Overview
Sweden technology and industrial group's Q1 net sales were flat and missed analyst expectations
Q1 EBITA declined 2% and missed analyst expectations
Order intake rose 2%, led by medical technology and pharma segments
Outlook
Company says order intake and backlog continued to improve in the first quarter
Indutrade notes significant market uncertainty due to geopolitical situation and economic recovery
Company sees strong order backlog and diversified structure supporting conditions for profitable growth
Result Drivers
MIXED DEMAND - Co said demand trends varied across segments, with strength in medical technology and pharma but weaker demand in infrastructure and construction
LONGER LEAD TIMES - Weakest organic net sales growth in Process, Energy & Water business area attributed to longer lead times in energy and process industry segments
ACQUISITION IMPACT - Acquisitions contributed 5% to net sales and 7% to EBITA, but were offset by weak sales and higher expenses
Company press release: ID:nMFN264SvH
Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Sales
Miss
SEK 8.06 bln
SEK 8.19 bln (6 Analysts)
Q1 EPS
SEK 1.64
Q1 Net Income
SEK 599 mln
Q1 EBITA
Miss
SEK 1.07 bln
SEK 1.12 bln (4 Analysts)
Q1 EBITA Margin
13.30%
Q1 Orders
SEK 8.61 bln
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", 4 "hold" and no "sell" or "strong sell"
Wall Street's median 12-month price target for Indutrade AB is SEK264.00, about 4.9% above its April 23 closing price of SEK251.60
The stock recently traded at 27 times the next 12-month earnings vs. a P/E of 28 three months ago
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)